Vaccine adjuvant uses of poly-IC and derivatives

Expert Review of Vaccines

Volumn 14, Issue 3, 2015, Pages 447-459

  Martins, Karen A O ^a   Bavari, Sina ^a   Salazar, Andres M ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Oncovir Inc   (United States)

Author keywords

Adaptive immunity; adjuvant; ampligen; hiltonol; innate immunity; interferons; PAMP; poly IC; poly ICLC; TLR3; vaccine

Indexed keywords

ADJUVANT; ANTIGEN; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; INFLUENZA VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; RINTATOLIMOD; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG STRUCTURE; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; HUMANS; POLY I-C; VACCINES;

EID: 84923102478     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.966085     Document Type: Review

References (159)

1. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503
2. Steinhagen F, Kinjo T, Bode C, et al. TLR-based immune adjuvants. Vaccine 2011;29:3341-55
3. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011;12:509-17
4. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011;10: 539-50
5. Hafner AM, Corthesy B, Merkle HP. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 2013;65:1386-99
6. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-608
7. Lambrecht BN, Kool M, Willart MA, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21: 23-9
8. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007;178:5271-6
9. Oleszycka E, Lavelle EC. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 2014;28C:1-5
10. Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 2010;128:29-35
11. Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10:499-511
12. Mbow ML, De Gregorio E, Valiante NM, et al. New adjuvants for human vaccines. Curr Opin Immunol 2010;22:411-16
13. Caskey M, Lefebvre F, Filali-Mouhim A, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011;208:2357-66
14. Chew V, Tow C, Huang C, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012;104:1796-807
15. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009;206:1589-602
16. Flynn BJ, Kastenmuller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci USA 2011;108:7131-6
17. Nagato T, Lee YR, Harabuchi Y, et al. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res 2014;20:1223-34
18. Wick DA, Webb JR. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine 2011;29:7857-66
19. Zhu X, Fallert-Junecko BA, Fujita M, et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 2010;59:1401-9
20. Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007;5:10
21. Stahl-Hennig C, Eisenblatter M, Jasny E, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009;5:e1000373
22. Kajiwara K, Morishima H, Akiyama K, et al. Expression and function of the inducible costimulator ligand B7-H2 in human airway smooth muscle cells. Allergol Int 2009;58:573-83
23. Wang Y, Cella M, Gilfillan S, et al. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 2010;184:2751-5
24. Mitoma H, Hanabuchi S, Kim T, et al. The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome. Immunity 2013;39: 123-35
25. Chattopadhyay S, Sen GC. dsRNA-Activation of TLR3 and RLR Signaling: gene Induction-Dependent and Independent Effects. J Interferon Cytokine Res 2014;34:427-36
26. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8
27. Kato H, Takeuchi O, Mikamo-Satoh E, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008;205:1601-10
28. Nemes MM, Tytell AA, Lampson GP, et al. Inducers of interferon and host resistance. VI. Antiviral efficacy of poly I:C in animal models. Proc Soc Exp Biol Med 1969;132: 776-83
29. Schreiner B, Voss J, Wischhusen J, et al. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J 2006;20:118-20
30. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-17
31. Lech M, Avila-Ferrufino A, Skuginna V, et al. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 2010;22:717-28
32. Robinson RA, DeVita VT, Levy HB, et al. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976;57:599-602
33. Carter WA, Pitha PM, Marshall LW, et al. Structural requirements of the rI n-rC n complex for induction of human interferon. J Mol Biol 1972;70:567-87
34. Do Y, Didierlaurent AM, Ryu S, et al. Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine 2012;30:6359-67
35. Cheong C, Choi JH, Vitale L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010;116:3828-38
36. Gowen BB, Wong MH, Jung KH, et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly (I:C): differential recognition of synthetic dsRNA molecules. J Immunol 2007;178: 5200-8
37. Ichinohe T, Kawaguchi A, Tamura S, et al. Intranasal immunization with H5N1 vaccine plus Poly I:poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007;9:1333-40
38. Ichinohe T, Ainai A, Tashiro M, et al. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009;27:6276-9
39. Avril T, de Tayrac M, Leberre C, et al. Not all polyriboinosinic-polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs. J Immunother 2009;32:353-62
40. Ma Y, Ross AC. Toll-like receptor 3 ligand and retinoic acid enhance germinal center formation and increase the tetanus toxoid vaccine response. Clin Vaccine Immunol 2009;16:1476-84
41. Hu F, Yu X, Wang H, et al. ER stress and its regulator X-box-binding protein-1 enhance polyIC-induced innate immune response in dendritic cells. Eur J Immunol 2011;41:1086-97
42. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 2006;103:8459-64
43. Matsumoto M, Kikkawa S, Kohase M, et al. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002;293:1364-9
44. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-5
45. Le Bon A, Schiavoni G, D'Agostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70
46. Le Bon A, Thompson C, Kamphuis E, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006;176:2074-8
47. Zou J, Kawai T, Tsuchida T, et al. Poly IC triggers a cathepsin D-and IPS-1-dependent pathway to enhance cytokine production and mediate dendritic cell necroptosis. Immunity 2013;38:717-28
48. Lauterbach H, Bathke B, Gilles S, et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 2010;207:2703-17
49. Kelly A, Fahey R, Fletcher JM, et al. CD141(+) myeloid dendritic cells are enriched in healthy human liver. J Hepatol 2014;60:135-42
50. Ding Y, Wilkinson A, Idris A, et al. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo. J Immunol 2014;192:1982-9
51. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-3
52. Oshiumi H, Matsumoto M, Funami K, et al. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003;4:161-7
53. Swiecki M, Wang Y, Vermi W, et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011;208:2367-74
54. Reimer T, Brcic M, Schweizer M, et al. poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J Leukoc Biol 2008;83:1249-57
55. Hochrein H, Shortman K, Vremec D, et al. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001;166:5448-55
56. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly (I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999;163:57-61
57. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-15
58. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433: 887-92
59. Durand V, Wong SY, Tough DF, et al. IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists. Vaccine 2006;24(Suppl 2):S2-22-3
60. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-30
61. Curtsinger JM, Valenzuela JO, Agarwal P, et al. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174: 4465-9
62. Kolumam GA, Thomas S, Thompson LJ, et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005;202:637-50
63. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. Cutting Edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 2006;176:3315-19
64. Wiesel M, Kratky W, Oxenius A. Type I IFN substitutes for T cell help during viral infections. J Immunol 2011;186:754-63
65. Perret R, Sierro SR, Botelho NK, et al. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 2013;73:6597-608
66. Ngoi SM, Tovey MG, Vella AT. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J Immunol 2008;181:7670-80
67. Gunthner R, Kumar VR, Lorenz G, et al. Pattern-recognition receptor signaling regulator mRNA expression in humans and mice, and in transient inflammation or progressive fibrosis. Int J Mol Sci 2013;14: 18124-47
68. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-12
69. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8
70. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002;23:375-8
71. Ferrero I, Held W, Wilson A, et al. Mouse CD11c(+) B220(+) Gr1(+) plasmacytoid dendritic cells develop independently of the T-cell lineage. Blood 2002;100:2852-7
72. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207: 1247-60
73. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000;164: 5998-6004
74. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-9
75. Heinz S, Haehnel V, Karaghiosoff M, et al. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 2003;278:21502-9
76. Lundberg AM, Drexler SK, Monaco C, et al. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 2007;110: 3245-52
77. Mian MF, Ahmed AN, Rad M, et al. Length of dsRNA (poly I:C) drives distinct innate immune responses, depending on the cell type. J Leukoc Biol 2013;94:1025-36
78. Trumpfheller C, Caskey M, Nchinda G, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008;105:2574-9
79. Engel AL, Holt GE, Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 2011;4: 275-89
80. Brodsky I, Strayer DR, Krueger LJ, et al. Clinical studies with ampligen (mismatched double-stranded RNA). J Biol Response Mod 1985;4:669-75
81. Hearl WG, Johnston MI. A misaligned double-stranded RNA, poly(I).poly(C12, U), induces accumulation of 2', 5'-oligoadenylates in mouse tissues. Biochem Biophys Res Commun 1986;138: 40-6
82. Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C (12)U] (Ampligen R). Vaccine 2003;21: 787-90
83. Navabi H, Jasani B, Reece A, et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009;27:107-15
84. Welters MJ, Bijker MS, van den Eeden SJ, et al. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 2007;25: 1379-89
85. Levy HB, Baer G, Baron S, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975;132:434-9
86. Sammons ML, Stephen EL, Levy HB, et al. Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother 1977;11:80-3
87. Martins KA, Steffens JT, van Tongeren SA, et al. Toll-like receptor agonist augments virus-like particle-mediated protection from ebola virus with transient immune activation. PLoS One 2014;9:e89735
88. Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005;22: 175-84
89. Zhu X, Fujita M, Snyder LA, et al. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 2011;104:83-92
90. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3
91. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2013. [Epub ahead of print]
92. Gelao L, Criscitiello C, Esposito A, et al. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014;6:914-33
93. Park H, Adamson L, Ha T, et al. Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein-Induced T Cell Responses In Nonhuman Primates. J Immunol 2013;190: 4103-15
94. Houston WE, Crabbs CL, Stephen EL, et al. Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun 1976;14:318-19
95. Stephen EL, Hilmas DE, Mangiafico JA, et al. Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Science 1977;197:1289-90
96. Ichinohe T, Ainai A, Ami Y, et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 2010;82:1754-61
97. Tewari K, Flynn BJ, Boscardin SB, et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010;28:7256-66
98. Kastenmuller K, Espinosa DA, Trager L, et al. Full-length P. falciparum circumsporozoite protein administered with poly-ICLC or GLA/SE elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect Immun 2012; 81(3):789-800
99. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 2009;69:9012-19
100. Ohlfest JR, Andersen BM, Litterman AJ, et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol 2013;190:613-20
101. Thompson KA, Strayer DR, Salvato PD, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996;15:580-7
102. Carter WA, Ventura D, Shapiro DE, et al. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease. Int J Immunopharmacol 1991;13 Suppl 1:69-76
103. Mitchell WM, Montefiori DC, Robinson WE Jr, et al. Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet 1987;1:890-2
104. Montefiori DC, Pellegrino MG, Robinson WE Jr, et al. Inhibition of HIV-1 proviral DNA synthesis and RNA accumulation by mismatched dsRNA. Biochem Biophys Res Commun 1989;158: 943-50
105. Montefiori DC, Robinson WE Jr, Mitchell WM. Mismatched dsRNA (ampligen) induces protection against genomic variants of the human immunodeficiency virus type 1 (HIV-1) in a multiplicity of target cells. Antiviral Res 1988;9:47-55
106. Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S88-95
107. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 1994;8:599-604
108. Strayer DR, Carter WA, Stouch BC, et al. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One 2012;7:e31334
109. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27: 3401-4
110. Lampkin BC, Levine AS, Levy H, et al. Phase II trial of poly(I, C)-LC, an interferon inducer, in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. J Biol Response Mod 1985;4:531-7
111. Stevenson HC, Abrams PG, Schoenberger CS, et al. A phase I evaluation of poly(I, C)-LC in cancer patients. J Biol Response Mod 1985;4:650-5
112. Ewel CH, Urba WJ, Kopp WC, et al. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res 1992;52:3005-10
113. Salazar AM, Levy HB, Ondra S, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996;38: 1096-103; discussion 1103-1094
114. Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009;91:183-9
115. Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol 2009;91:175-82
116. Rosenfeld MR, Chamberlain MC, Grossman SA, et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 2010;12:1071-7
117. Hartman LL, Crawford JR, Makale MT, et al. Pediatric Phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol 2013;36(6):451-7
118. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6
119. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17:1603-15
120. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18:6497-508
121. Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 2014;20:1355-65
122. Morse MA, Chapman R, Powderly J, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011;17:4844-53
123. Salazar AM, Erlich RB, Mark A, et al. Therapeutic in situ autovaccination against solid cancers with intratumoral Poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2014;2:720-4
124. Garaude J, Kent A, van Rooijen N, et al. Simultaneous targeting of toll-and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012;4; 120ra116
125. McNally B, Willette M, Ye F, et al. Intranasal administration of dsRNA analog poly(I:C) induces interferon-alpha receptor-dependent accumulation of antigen experienced T cells in the airways. PLoS One 2012;7:e51351
126. Perrot I, Deauvieau F, Massacrier C, et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol 2010;185:2080-8
127. Lang KS, Recher M, Junt T, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005;11:138-45
128. Weck MM, Grunebach F, Werth D, et al. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 2007;109:3890-4
129. Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol 2010;22:124-30
130. Mouries J, Moron G, Schlecht G, et al. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 2008;112:3713-22
131. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006;7: 165-72
132. Young LJ, Wilson NS, Schnorrer P, et al. Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. Proc Natl Acad Sci USA 2007;104:17753-8
133. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol 2013;9:361-73
134. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011;11:807-22
135. Tacken PJ, Zeelenberg IS, Cruz LJ, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011;118:6836-44
136. De Temmerman ML, Rejman J, Demeester J, et al. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 2011;16: 569-82
137. Jain S, O'Hagan DT, Singh M. The long-term potential of biodegradable poly (lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011;10:1731-42
138. Katare YK, Muthukumaran T, Panda AK. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005;301: 149-60
139. Reece JC, Vardaxis NJ, Marshall JA, et al. Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes. Immunol Cell Biol 2001;79:255-63
140. Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008;38:1404-13
141. Rosenthal JA, Chen L, Baker JL, et al. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. Curr Opin Biotechnol 2013;28C:51-8
142. Kwon YJ, James E, Shastri N, et al. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA 2005;102:18264-8
143. Bandyopadhyay A, Fine RL, Demento S, et al. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 2011;32:3094-105
144. Raghuwanshi D, Mishra V, Das D, et al. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol Pharm 2012;9:946-56
145. Scallan CD, Tingley DW, Lindbloom JD, et al. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 2013;20:85-94
146. Peters W, Brandl JR, Lindbloom JD, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013;31:1752-8
147. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J 2013;15: 85-94
148. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, et al. Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines 2011;10: 95-107
149. Zhang XQ, Dahle CE, Weiner GJ, et al. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci 2007;96:3283-92
150. Schlosser E, Mueller M, Fischer S, et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008;26:1626-37
151. Ilyinskii PO, Roy CJ, O'Neil CP, et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine 2014;32: 2882-95
152. Li Y, Hu Y, Jin Y, et al. Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. J Gene Med 2011;13:60-72
153. Wong JP, Yang H, Nagata L, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 1999;17:1788-95
154. Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol 2012;90:492-7
155. Dondi E, Rogge L, Lutfalla G, et al. Down-modulation of responses to type I IFN upon T cell activation. J Immunol 2003;170:749-56
156. Dondi E, Roue G, Yuste VJ, et al. A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 2004;173:3740-7
157. Marshall HD, Urban SL, Welsh RM. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol 2011;85:5929-39
158. Lampkin BC, Levine AS, Levy H, et al. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res 1985;45:5904-9
159. Levine AS, Sivulich M, Wiernik PH, et al. Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res 1979;39:1645-50